Health Care·Biotechnology·$20.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.52 | N/A | +13.70% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.52 | N/A | +13.70% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about ongoing market conditions and the impact on future performance. They reiterated their commitment to innovation and research.
Management acknowledged the challenges faced in the current market environment.
They emphasized a focus on long-term strategies despite short-term setbacks.
Moderna's earnings report shows a significant loss per share, which was better than some expectations but still reflects ongoing challenges. The stock fell by over 5% in reaction, indicating investor concern about the company's current trajectory and lack of revenue updates. Without guidance, uncertainty remains about future performance and market positioning.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
REVVITY INC
Apr 28, 2025